Study of the ReGelTec HYDRAFIL System (NCT04984629) | Clinical Trial Compass
CompletedNot Applicable
Study of the ReGelTec HYDRAFIL System
Canada35 participantsStarted 2022-01-04
Plain-language summary
A study designed to treat patients with back pain associated with degenerative lumbar disc disease.
Who can participate
Age range22 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Present with predominant low back pain and symptoms of DDD of the lumbar region of at least 6 months duration
* Failure to have their symptoms resolve or reduce following 6 months conservative care (pain medication and/or physical therapy)
* Male or female patients aged 22 to 80 years, inclusive
* Presence of DDD on magnetic resonance imaging (MRI) scan with global disc degeneration. Modified Pfirrmann grades 5 to 8 as characterized by MRI
* The presence of one or two symptomatic discs exhibiting degeneration contained within a competent outer annulus as determined by MRI and provocative discography and/or anaesthetic discography at L1-S1
* Patients who are legally competent and able to understand the nature, scope and aim of the clinical investigation
* Signed an informed subject consent form in a language in which they are fluent
Exclusion Criteria:
* History of or current systemic or local infection
* Annular tear or defect that shows free contrast extravasation into the epidural space during or after discography
* Presence of disc herniation that accounts for the majority of the patient's symptoms
* Subjects with Modic type 3 changes
* Subjects with trans-endplate disc herniations or Schmorl's nodes
* Neurogenic claudication due to spinal stenosis
* Previous back surgery at the target level of the lumbar spine
* Evidence of severe compression of cauda equina
* Spinal segmental instability (spondylolysis or spondylolisthesis: Grade \>1), spinal can…